JP2005500300A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005500300A5 JP2005500300A5 JP2003506277A JP2003506277A JP2005500300A5 JP 2005500300 A5 JP2005500300 A5 JP 2005500300A5 JP 2003506277 A JP2003506277 A JP 2003506277A JP 2003506277 A JP2003506277 A JP 2003506277A JP 2005500300 A5 JP2005500300 A5 JP 2005500300A5
- Authority
- JP
- Japan
- Prior art keywords
- medicament
- preparation
- compound
- treatment
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 15
- 239000003814 drug Substances 0.000 claims 12
- 230000002265 prevention Effects 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 4
- 150000002596 lactones Chemical class 0.000 claims 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 3
- 125000001033 ether group Chemical group 0.000 claims 3
- 230000036470 plasma concentration Effects 0.000 claims 3
- 108010001127 Insulin Receptor Proteins 0.000 claims 2
- 102100036721 Insulin receptor Human genes 0.000 claims 2
- YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 claims 2
- 238000001802 infusion Methods 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- YJGVMLPVUAXIQN-HAEOHBJNSA-N picropodophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-HAEOHBJNSA-N 0.000 claims 2
- NOVZFMNCTCKLPF-UHFFFAOYSA-N 2,5-bis(aziridin-1-yl)-3,6-dipropoxycyclohexa-2,5-diene-1,4-dione Chemical compound O=C1C(OCCC)=C(N2CC2)C(=O)C(OCCC)=C1N1CC1 NOVZFMNCTCKLPF-UHFFFAOYSA-N 0.000 claims 1
- 206010000599 Acromegaly Diseases 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- ZGLXUQQMLLIKAN-UHFFFAOYSA-N Deoxypicropodophyllin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3CC3C2C(OC3)=O)=C1 ZGLXUQQMLLIKAN-UHFFFAOYSA-N 0.000 claims 1
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 claims 1
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 claims 1
- 101710184277 Insulin-like growth factor 1 receptor Proteins 0.000 claims 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 claims 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- 238000007887 coronary angioplasty Methods 0.000 claims 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims 1
- 239000000824 cytostatic agent Substances 0.000 claims 1
- ZGLXUQQMLLIKAN-SVIJTADQSA-N deoxypodophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3C[C@@H]3[C@@H]2C(OC3)=O)=C1 ZGLXUQQMLLIKAN-SVIJTADQSA-N 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 150000002170 ethers Chemical class 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 230000026731 phosphorylation Effects 0.000 claims 1
- 238000006366 phosphorylation reaction Methods 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0102168A SE0102168D0 (sv) | 2001-06-19 | 2001-06-19 | New use and new compounds |
| SE0102168-2 | 2001-06-19 | ||
| US30043101P | 2001-06-26 | 2001-06-26 | |
| US60/300,431 | 2001-06-26 | ||
| PCT/SE2002/001202 WO2002102804A1 (en) | 2001-06-19 | 2002-06-19 | New use of specific cyclolignans |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009134006A Division JP2009242406A (ja) | 2001-06-19 | 2009-06-03 | 特定のシクロリグナン類の新しい使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005500300A JP2005500300A (ja) | 2005-01-06 |
| JP2005500300A5 true JP2005500300A5 (https=) | 2006-01-05 |
| JP5071910B2 JP5071910B2 (ja) | 2012-11-14 |
Family
ID=20284528
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003506278A Pending JP2004534078A (ja) | 2001-06-19 | 2002-06-19 | シクロリグナン類の新規の使用および新規のシクロリグナン類 |
| JP2003506277A Expired - Fee Related JP5071910B2 (ja) | 2001-06-19 | 2002-06-19 | 特定のシクロリグナン類の新しい使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003506278A Pending JP2004534078A (ja) | 2001-06-19 | 2002-06-19 | シクロリグナン類の新規の使用および新規のシクロリグナン類 |
Country Status (15)
| Country | Link |
|---|---|
| US (7) | US7348358B2 (https=) |
| EP (5) | EP1498121B1 (https=) |
| JP (2) | JP2004534078A (https=) |
| KR (1) | KR100940055B1 (https=) |
| CN (3) | CN100503611C (https=) |
| AT (1) | ATE441411T1 (https=) |
| AU (2) | AU2002314671B2 (https=) |
| CA (2) | CA2451047C (https=) |
| DK (1) | DK1498121T3 (https=) |
| ES (1) | ES2333014T3 (https=) |
| NO (1) | NO332642B1 (https=) |
| NZ (2) | NZ530172A (https=) |
| PT (1) | PT1498121E (https=) |
| SE (1) | SE0102168D0 (https=) |
| WO (2) | WO2002102805A1 (https=) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0102168D0 (sv) * | 2001-06-19 | 2001-06-19 | Karolinska Innovations Ab | New use and new compounds |
| SE0203746D0 (sv) * | 2002-12-18 | 2002-12-18 | Karolinska Innovations Ab | New compounds |
| SE0203747D0 (sv) * | 2002-12-18 | 2002-12-18 | Karolinska Innovations Ab | New use |
| SE0301202D0 (sv) * | 2003-04-24 | 2003-04-24 | Orteca Ab C O Karolinska Innov | New use and new compounds |
| US7342114B2 (en) | 2003-07-01 | 2008-03-11 | California Pacific Medical Center | Podophyllotoxin derivatives |
| US20050075358A1 (en) * | 2003-10-06 | 2005-04-07 | Carboni Joan M. | Methods for treating IGF1R-inhibitor induced hyperglycemia |
| UA83509C2 (en) * | 2003-10-15 | 2008-07-25 | Оси Фармасьютикалз, Инк. | Imidazopyrazines as tyrosine kinase inhibitors |
| WO2005082415A2 (en) * | 2004-02-25 | 2005-09-09 | Dana Farber Cancer Institute, Inc. | Inhibitors of insulin-like growth factor receptor-1 for inhibiting tumor cell growth |
| EP1732898B1 (en) | 2004-03-12 | 2008-01-23 | Analytecon S.A. | Tetrahydroisoquinoline- and tetrahydrobenzazepine derivatives as igf-1r inhibitors |
| EP2168968B1 (en) | 2004-04-02 | 2017-08-23 | OSI Pharmaceuticals, LLC | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors |
| TW200613306A (en) | 2004-07-20 | 2006-05-01 | Osi Pharm Inc | Imidazotriazines as protein kinase inhibitors |
| US7566721B2 (en) * | 2005-08-08 | 2009-07-28 | Osi Pharmaceuticals, Inc. | Substituted thienol[2,3-d]pyrimidines as kinase inhibitors |
| CA2623125A1 (en) | 2005-09-20 | 2007-03-29 | Osi Pharmaceuticals, Inc. | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
| AR057960A1 (es) * | 2005-12-02 | 2007-12-26 | Osi Pharm Inc | Inhibidores de proteina quinasa biciclicos |
| US8575164B2 (en) * | 2005-12-19 | 2013-11-05 | OSI Pharmaceuticals, LLC | Combination cancer therapy |
| AU2007218217A1 (en) * | 2006-02-24 | 2007-08-30 | Axelar Ab | Use of cyclolignans for the treatment of type 2 diabetes and as contraceptives |
| EP2056808A4 (en) * | 2006-08-28 | 2009-12-23 | Univ California | Small molecule potentiator of hormonal therapy for breast cancer |
| US20110046144A1 (en) * | 2008-01-18 | 2011-02-24 | Mulvihill Mark J | Imidazopyrazinol derivatives for the treatment of cancers |
| WO2009100349A1 (en) * | 2008-02-09 | 2009-08-13 | The Trustees Of Columbia University In The City Of New York | Analogues of (-)-picropodophyllin, synthesis and uses thereof |
| WO2009108857A2 (en) * | 2008-02-27 | 2009-09-03 | Combithera, Inc. | Combination therapy for prostate cancer |
| EP2274617A4 (en) * | 2008-04-10 | 2011-11-09 | Massachusetts Inst Technology | METHOD OF DETECTING AND USING MEDIUM-TREATMENT AID ON CANCER STEM CELLS |
| ES2396613T3 (es) * | 2008-05-19 | 2013-02-22 | OSI Pharmaceuticals, LLC | Imidazopirazinas e imidazotriazinas sustituidas |
| EP2349235A1 (en) | 2008-11-07 | 2011-08-03 | Triact Therapeutics, Inc. | Use of catecholic butane derivatives in cancer therapy |
| WO2010099139A2 (en) | 2009-02-25 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Combination anti-cancer therapy |
| JP2012519170A (ja) | 2009-02-26 | 2012-08-23 | オーエスアイ・ファーマシューティカルズ，エルエルシー | 生体内の腫瘍細胞のｅｍｔステータスをモニターするためのｉｎｓｉｔｕ法 |
| WO2010099363A1 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
| WO2010099138A2 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
| WO2010099364A2 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
| US8513415B2 (en) | 2009-04-20 | 2013-08-20 | OSI Pharmaceuticals, LLC | Preparation of C-pyrazine-methylamines |
| EP2427192A1 (en) * | 2009-05-07 | 2012-03-14 | OSI Pharmaceuticals, LLC | Use of osi-906 for treating adrenocortical carcinoma |
| WO2010138686A1 (en) * | 2009-05-29 | 2010-12-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Mdri-inverse agents |
| US7924203B2 (en) * | 2009-06-12 | 2011-04-12 | Analog Devices, Inc. | Most significant bits analog to digital converter, and an analog to digital converter including a most significant bits analog to digital converter |
| US20100316639A1 (en) | 2009-06-16 | 2010-12-16 | Genentech, Inc. | Biomarkers for igf-1r inhibitor therapy |
| CA2783665A1 (en) | 2010-03-03 | 2011-09-09 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
| WO2011109572A2 (en) | 2010-03-03 | 2011-09-09 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
| EP2544672A1 (en) | 2010-03-09 | 2013-01-16 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
| JP5642283B2 (ja) * | 2010-08-31 | 2014-12-17 | アクセラー エービー | シクロリグナンを調製するための新たな方法 |
| SG189295A1 (en) | 2010-10-08 | 2013-05-31 | Axelar Ab | Picropodophyllin polymorphs b or c for use in cancer therapy |
| WO2012116040A1 (en) | 2011-02-22 | 2012-08-30 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma |
| WO2012149014A1 (en) | 2011-04-25 | 2012-11-01 | OSI Pharmaceuticals, LLC | Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment |
| JP5892508B2 (ja) * | 2011-05-23 | 2016-03-23 | 国立大学法人 鹿児島大学 | 抗腫瘍剤及びその製造方法 |
| WO2013124382A1 (en) * | 2012-02-24 | 2013-08-29 | Nestec S.A. | Peltatin for use in the treatment of cardiovascular disorders |
| WO2013132263A1 (en) | 2012-03-09 | 2013-09-12 | Axelar Ab | Picropodophyllin derivatives for use in therapy |
| WO2013132262A1 (en) | 2012-03-09 | 2013-09-12 | Axelar Ab | Picropodophyllin derivatives |
| WO2013152252A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
| JP5923375B2 (ja) * | 2012-04-24 | 2016-05-24 | 花王株式会社 | Ｃｇｒｐ応答性促進剤 |
| WO2014102889A1 (ja) * | 2012-12-25 | 2014-07-03 | 国立大学法人鹿児島大学 | 抗腫瘍剤及びその製造方法 |
| US9834575B2 (en) | 2013-02-26 | 2017-12-05 | Triact Therapeutics, Inc. | Cancer therapy |
| CA2912254C (en) * | 2013-05-10 | 2021-06-08 | M. Alphabet 2, L.L.C. | Methods of treating skin conditions using cyclolignan compounds |
| WO2015035410A1 (en) | 2013-09-09 | 2015-03-12 | Triact Therapeutic, Inc. | Cancer therapy |
| CN104434909A (zh) * | 2013-09-12 | 2015-03-25 | 中国药科大学 | 一种去氧鬼臼毒素作为胰岛素样生长因子受体拮抗剂用途 |
| WO2015168255A1 (en) | 2014-04-29 | 2015-11-05 | Whitehead Institute For Biomedical Research | Methods and compositions for targeting cancer stem cells |
| US10087194B2 (en) | 2015-10-27 | 2018-10-02 | California Pacific Medical Center | Podophyllotoxin derivatives and their use |
| CN106937529B (zh) | 2015-10-27 | 2021-02-05 | 加州太平洋医疗中心 | 鬼臼毒素衍生物及其应用 |
| CN110669054B (zh) * | 2018-07-03 | 2022-04-26 | 南京药石科技股份有限公司 | 胰岛素样生长因子-1受体酪氨酸激酶抑制剂及其用途 |
| KR102378151B1 (ko) | 2020-05-11 | 2022-03-24 | 주식회사 제이앤씨사이언스 | 베타-아포피크로포도필린의 신규한 유도체 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2825730A (en) * | 1953-02-04 | 1958-03-04 | Thompson Boyce Plant Res | Organic compounds |
| US4342777A (en) * | 1979-03-29 | 1982-08-03 | The United States Of America As Represented By The Secretary Of Agriculture | Polybutylbenzylphenols and benzyl-3,4-methylenedioxybenzenes in insect population control |
| EP0207124B1 (en) * | 1984-12-28 | 1991-10-09 | Conpharm Ab | Use of podophyllotoxin and derivatives thereof |
| NO170760C (no) | 1985-01-10 | 1992-12-02 | Tanabe Seiyaku Co | Analogifremgangsmaate for fremstilling av terapeutisk aktive nafthalenderivater |
| SE468213B (sv) * | 1986-06-27 | 1992-11-23 | Conpharm Ab | Anvaendning av podophyllotoxin eller ett derivat daerav till framstaellning av en farmakologisk beredning foer behandling av kollagenoser, saerskilt reumatoid artrit |
| KR890700023A (ko) * | 1986-11-19 | 1989-03-02 | 케맥스 파마슈우티칼스 인코포레이티드 | 리폭시게나제 저해제 |
| SE464167B (sv) * | 1989-07-31 | 1991-03-18 | Analytecon Sa | Topisk farmaceutisk beredning av podophyllotoxin |
| CN1075316A (zh) | 1992-10-22 | 1993-08-18 | 布里斯托尔-米尔斯·斯奎布公司 | 表鬼臼毒中间体的制备方法 |
| GB9422947D0 (en) | 1994-11-14 | 1995-01-04 | Univ Salamanca | Immunosuppressive cyclolignan derivatives |
| JPH09194368A (ja) * | 1996-01-11 | 1997-07-29 | Pola Chem Ind Inc | ポドフィロトキシン誘導体及びそれからなる新規細胞分化誘導剤 |
| US5726027A (en) | 1996-03-08 | 1998-03-10 | The Regents Of The University Of California | Method for treatment of insulin resistance |
| US7020563B1 (en) * | 1997-11-27 | 2006-03-28 | Commonwealth Scientific And Industrial Research Organisation | Method of designing agonists and antagonists to IGF receptor |
| WO2000000238A1 (en) | 1998-06-26 | 2000-01-06 | Quanam Medical Corporation | Topoisomerase inhibitors for prevention of restenosis |
| WO2001052826A2 (en) * | 2000-01-20 | 2001-07-26 | Supratek Pharma Inc. | Novel podophyllotoxin compositions |
| ATE339423T1 (de) * | 2000-11-20 | 2006-10-15 | Song-Bae Kim | Verfahren zur herstellung von 4'-o-substituierten 4'-demethyl-1 desoxypodophyllotoxinderivaten und geometrischen isomeren davon ,und antikrebspräparat, das diese enthält |
| SE0102168D0 (sv) * | 2001-06-19 | 2001-06-19 | Karolinska Innovations Ab | New use and new compounds |
| US7714139B2 (en) * | 2003-03-27 | 2010-05-11 | Lankenau Institute For Medcial Research | IDO inhibitors and methods of use |
| SE0301202D0 (sv) * | 2003-04-24 | 2003-04-24 | Orteca Ab C O Karolinska Innov | New use and new compounds |
-
2001
- 2001-06-19 SE SE0102168A patent/SE0102168D0/xx unknown
-
2002
- 2002-06-19 US US10/481,441 patent/US7348358B2/en not_active Expired - Fee Related
- 2002-06-19 CN CNB028161904A patent/CN100503611C/zh not_active Expired - Fee Related
- 2002-06-19 NO NO20035648A patent/NO332642B1/no not_active IP Right Cessation
- 2002-06-19 EP EP04024370A patent/EP1498121B1/en not_active Expired - Lifetime
- 2002-06-19 JP JP2003506278A patent/JP2004534078A/ja active Pending
- 2002-06-19 CA CA2451047A patent/CA2451047C/en not_active Expired - Fee Related
- 2002-06-19 WO PCT/SE2002/001223 patent/WO2002102805A1/en not_active Ceased
- 2002-06-19 JP JP2003506277A patent/JP5071910B2/ja not_active Expired - Fee Related
- 2002-06-19 US US10/480,800 patent/US20040167208A1/en not_active Abandoned
- 2002-06-19 EP EP02741588A patent/EP1397369A1/en not_active Ceased
- 2002-06-19 WO PCT/SE2002/001202 patent/WO2002102804A1/en not_active Ceased
- 2002-06-19 EP EP10153209A patent/EP2186513A1/en not_active Withdrawn
- 2002-06-19 NZ NZ53017202A patent/NZ530172A/xx unknown
- 2002-06-19 CA CA2455328A patent/CA2455328C/en not_active Expired - Fee Related
- 2002-06-19 ES ES04024370T patent/ES2333014T3/es not_active Expired - Lifetime
- 2002-06-19 CN CNA2009101347598A patent/CN101606929A/zh active Pending
- 2002-06-19 DK DK04024370T patent/DK1498121T3/da active
- 2002-06-19 NZ NZ530290A patent/NZ530290A/en not_active IP Right Cessation
- 2002-06-19 PT PT04024370T patent/PT1498121E/pt unknown
- 2002-06-19 CN CN028162404A patent/CN1659171A/zh active Pending
- 2002-06-19 EP EP08150436A patent/EP1938818A3/en not_active Withdrawn
- 2002-06-19 EP EP08150437A patent/EP1938819A3/en not_active Withdrawn
- 2002-06-19 KR KR1020037016630A patent/KR100940055B1/ko not_active Expired - Fee Related
- 2002-06-19 AU AU2002314671A patent/AU2002314671B2/en not_active Ceased
- 2002-06-19 AU AU2002311731A patent/AU2002311731B8/en not_active Ceased
- 2002-06-19 AT AT04024370T patent/ATE441411T1/de active
-
2006
- 2006-02-03 US US11/346,294 patent/US7709526B2/en not_active Expired - Fee Related
-
2008
- 2008-01-29 US US12/021,578 patent/US7662851B2/en not_active Expired - Fee Related
- 2008-01-29 US US12/021,530 patent/US7629381B2/en not_active Expired - Fee Related
-
2009
- 2009-07-23 US US12/508,218 patent/US8389747B2/en not_active Expired - Fee Related
-
2010
- 2010-02-26 US US12/714,107 patent/US20100216728A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005500300A5 (https=) | ||
| CA2451047A1 (en) | Use of picropodophyllin derivatives for treatment of igf-1r mediated disorders | |
| FI111808B (fi) | Menetelmä uusien, taksaaneihin perustuvien farmaseuttisten koostumusten valmistamiseksi | |
| CN1047305C (zh) | 可注射的组合物 | |
| EA021757B1 (ru) | Фармацевтические комбинации, содержащий их набор, применение этих комбинаций и способ лечения заболеваний, связанных с клеточной пролиферацией, миграцией или апоптозом клеток миеломы или с ангиогенезом | |
| CN1195514C (zh) | 海鞘素 743的代谢物 | |
| JP2001247459A (ja) | 癌の組み合わせ療法 | |
| PL189311B1 (pl) | Nowe taksoidy, sposób ich wytwarzania i kompozycje farmaceutyczne zawierające te związki | |
| JP2012062329A (ja) | 併用化学療法 | |
| TW201818937A (zh) | 治療癌症之方法 | |
| JP2009513662A5 (https=) | ||
| JP2004517843A5 (https=) | ||
| JP2023513419A5 (https=) | ||
| CN114040765B (zh) | 癌症免疫治疗佐剂 | |
| JP2003525239A (ja) | タキサン化合物とのファルネシルタンパク質トランスフェラーゼ阻害剤の組み合わせ剤 | |
| EP2254570B1 (en) | Combination comprising paclitaxel for treating ovarian cancer | |
| JP2006510658A5 (https=) | ||
| JP2004517882A (ja) | トリプトライドプロドラッグを使用する抗癌処置 | |
| JP2010540649A5 (https=) | ||
| US6689811B2 (en) | Method of using caffeic acid phenethyl ester and analogs thereof as radiation sensitizers | |
| JPH02501930A (ja) | 薬学的化合物のための新規な用途 | |
| RU2007104176A (ru) | Синтез и применение (-)-бета-элемена, (-)-бета-элеменала, (-)-бета-элеменола, фторида (-)-бета-элемена и их аналогов, а также промежуточных продуктов и композитов | |
| Bouchard et al. | Novel taxanes: cabazitaxel case study | |
| RU2382784C2 (ru) | Новые пиперидинзамещенные диаминотиазолы | |
| CA2596084A1 (en) | Treatment of metastasized tumors with quinolinone benzimidazole compounds |